|Bid||167.23 x 100|
|Ask||167.69 x 200|
|Day's Range||166.10 - 168.08|
|52 Week Range||59.57 - 195.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||208.86|
Baltimore-based mutual fund giant T. Rowe Price has been arguing over the last few years that during times when the stock market isn't steadily rising, its actively managed mutual funds would outperform passively managed funds that mirror indexes.
Tom Vandeventer of the Tocqueville Opportunity Fund says it’s worth paying up for cloud-based services companies including ServiceNow, Nutanix and Workday.
Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders. One of the products under development, SAGE-718, is based on its NMDA Receptor program.
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders. The chart below shows the products under development, based on the drug discovery programs for Sage Therapeutics. The company classifies its products into two programs: GABA receptors and NMDA receptors.
Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company. Sage Therapeutics develops medicines for the treatment of life-altering central nervous system disorders such as Parkinson’s disease and postpartum depression.
CNBC's Jim Cramer makes the case to value the market just as it is. The "Mad Money" host also hears from the CEOs of Sage Therapeutics and Vistra Energy. In the lightning round, Cramer makes the case for buying shares of World Wrestling Entertainment.
Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 129,000 shares of its common stock to 31 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...
NEW YORK , June 25, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Investors have bought into the technology sector with fervor as markets enjoyed a brief period of tranquility just before politicians resumed their belligerent rhetoric.
As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.
As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.
SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.
On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.
SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.
Biotech stocks are nearing a big break out as measured by the SPDR S&P Biotech ETF ( XBI). The group is already having a strong start to 2018, quietly outpacing not only the S&P 500 but the most talked about sectors in the market, technology ( XLK) and consumer stocks ( XLY). The biotech ETF is sitting right below a significant resistance level at $97.90, the previous all-time high for the ETF, and should that price rise above technical resistance, it would mark a big breakout.
Sage Therapeutics Inc. shares dropped 3.3% in Thursday morning trade after the company announced a $90 million deal with Shionogi & Co. Ltd. for the clinical development and commercialization of its drug SAGE-217 in Japan, Taiwan and South Korea. Shionogi will also handle clinical development, regulatory filings and commercialization of SAGE-217 for major depressive disorder and any other indications in those countries.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial.
Sage Therapeutics lost some of its steam Wednesday, as shares dropped more than 3%, but analysts remained bullish on the biotech company's plans for an acute depression treatment.
NEW YORK, NY / ACCESSWIRE / June 13, 2018 / It was an exciting day for biotech stocks Sage Therapeutics and Galmed Pharmaceuticals. Sage rose higher after announcing that the FDA has allowed expedited development on its major depressive drug. Shares of Galmed soared to a new high after announcing positive results from its Phase 2b ARREST study.
Jim Cramer sits down with Sage Therapeutics CEO Jeff Jonas to hear about the novel treatments his company is testing for depression.